Know Cancer

forgot password

A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Age

Phase 1
5 Years
17 Years
Not Enrolling

Thank you

Trial Information

A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Age

This study is a randomized, double-blind Phase 1 study of FluMist vs. placebo in mild to
moderately immunocompromised children 5 to 17 years of age with cancer. The primary
objective of this study is to describe the safety of FluMist compared with placebo in mild
to moderately immunocompromised children with cancer. The secondary objectives of this study
are to describe the immune responses following vaccination with FluMist and to determine the
incidence and duration of viral replication following vaccination with FluMist.

The standard 0.5 mL dose of vaccine or placebo was administered intranasally. Patients were
evaluated at four visits scheduled between days 3-5, days 7-10, days 14-28, and days 35-42
for viral shedding via nasal swabs. Safety outcomes were collected at study clinic visits or
by telephone contact through 42 days post dose. Serious adverse events and significant new
medical conditions were collected through 180 days after receipt of investigational product.

Immune responses were measured by detection of influenza-specific antibodies as measured by
the standard hemagglutination inhibition (HAI) assay. Influenza-specific serum antibody
isotype levels were determined and nasal swab specimens were analyzed for the expression of
influenza-specific immunoglobulin A (IgA). Serum was analyzed for its ability to neutralize
viral particles from infecting Madin-Darby canine kidney cells (microneutralization).
Baseline immunosuppression as measured by expression of T- and B-lymphocyte subsets was
compared to immunosuppression at time points after vaccination. The duration of viral
replication and the titers of live-attenuated influenza virus shed was evaluated from nasal
swab specimens collected at scheduled time points after administration of FluMist.

Inclusion Criteria:

- Age 5 through 17 years of age (not yet reached their 18th birthday) at the time of
entry into the study;

- Patient's parent or legal guardian available by telephone during the course of the

- Written informed consent (assent if applicable) and Health Insurance Portability and
Accountability Act (HIPAA) authorization (if applicable) obtained from the patient's
parent or legal guardian;

- Ability of the patient or patient's parent/guardian to comply with the requirements
of the protocol;

- Currently receiving chemotherapy and/or radiation therapy for the treatment of cancer
or have received chemotherapy in the past 12 weeks;

- If the subject's underlying cancer is a solid tumor, current status must be stable
disease, partial response, or complete response to therapy; if the subject's
underlying disease is a hematologic malignancy, current status must be in remission;

- Estimated life expectancy of >1 year; and

- Currently has no worse than mild to moderate immunosuppression (meets none of the
exclusion criteria).

Exclusion Criteria:

- History of hypersensitivity to any component of FluMist, including egg or egg
products, or monosodium glutamate;

- History of hypersensitivity to gentamicin;

- Close contact with a severely immunocompromised patient (e.g., a hematopoietic stem
cell transplant patient, during those periods in which the immunocompromised patient
requires care in a protective environment);

- History of Guillain-Barré syndrome;

- History of asthma;

- Use of aspirin or salicylate-containing products in the 30 days prior to study
vaccination or expected receipt within the study duration;

- Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir,
and zanamivir) within 14 days prior to enrollment or expected receipt (unless
medically indicated) during this study;

- Currently receiving inhaled steroid therapy;

- Receipt of immunoglobulin within the past 90 days;

- Receipt of stem cell transplant;

- Acute febrile [>100.0°F (37.8°C) oral] illness or acute respiratory illness, e.g.,
cough or sore throat, within three days prior to enrollment;

- Administration of any live vaccine within 30 days prior to enrollment or if receipt
of another live vaccine is expected within 30 days after the vaccination in this

- Administration of any inactivated vaccine within two weeks prior to enrollment or if
receipt of another inactivated vaccine is expected within two weeks after the
vaccination in this study;

- Receipt of an investigational product studied under an investigational new drug (IND)
within 10 days prior to study entry or expected receipt of such an investigational
product within 10 days after study vaccination (Note: an investigational product not
studied under an IND is allowed at the investigator's discretion);

- Pregnancy or, in biologically capable females (e.g., menses within the last year),
not willing to agree to acceptable birth control for three months after study
vaccination (for those biologically capable, a urine pregnancy test must be performed
on the day of vaccination with a negative result);

- Female who is breastfeeding or lactating;

- Any condition or receipt of other medication that, in the opinion of the
investigator, might interfere with the evaluation of the vaccine or interpretation of
study results;

- At the study screening visit (within 16 days before study vaccination) a CD4+ T cell
percentage of <15%;

- At study entry, an absolute neutrophil count less than or equal to 500 cells/mm3;

- Receipt of high-dose systemic corticosteroids (≥ 2 mg/kg total of prednisone or
equivalent given daily or on alternating days) for ≥ 14 consecutive days within 30
days prior to or following study vaccination

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Outcome Measure:

Number of Participants Who Had Reactogenicity Events (REs)

Outcome Description:

Reactogenicity events (REs) are predefined solicited adverse events (AEs) that can potentially occur after vaccine administration. For the participants enrolled in this study REs include fever, runny nose/nasal congestion, sore throat, cough, vomiting, headache, muscle aches, chills, tiredness, and irritability.

Outcome Time Frame:

0-42 days after study vaccination

Safety Issue:


Principal Investigator

Raburn Mallory, MD

Investigator Role:

Study Director

Investigator Affiliation:

MedImmune LLC


United States: Food and Drug Administration

Study ID:




Start Date:

August 2005

Completion Date:

May 2008

Related Keywords:

  • Cancer
  • cancer, pediatric, influenza, vaccine



Vanderbilt University Nashville, Tennessee  37232-6305
University of Rochester School of Medicine & Dentistry Rochester, New York  14642
Stony Brook University Medical Center Stony Brook, New York  11794
St. Jude's Children's Research Hospital Memphis, Tennessee  38105
Children's Hospital Regional Medical Center Seattle, Washington  98105